Objective: To explore the clinical efficacy of aspirin in combined with ozagrel sodium in the treatment of acute cerebral infarction (ACI). Methods: A total of 120 patients with ACI who were admitted in our hospital from May, 2015 to May, 2016 were included in the study and randomized into the study group and the control group with 60 cases in each group. The patients in the two groups were given cerebral edema alleviating, brain cell protecting, cerebral circulation improving, and blood pressure controlling. The patients in the study group were given aspirin enteric-coated tablets, 0.1 g/time, 1 time/d. On the above basis, the patients in the study group were given ozagrel sodium (80 mg) + 0.9% NaCl (250 mL), ivdrip, 2 times/d. The patients in the two groups were treated for 14 d. The venous blood was extracted 1 d after admission and 14 d after treatment. The full automatic biochemical analyzer was used to detect PLT, PT, TT, FIB, and APTT. The radioimmunoassay was used to detect TXB2 and 6-K-PGF1α. The color Doppler ultrasound was used to detect IMT. Results: PLT, PT, TT, and APTT after treatment were not significantly different from those before treatment (P>0.05), but FIB was significantly reduced, and the reduced degree in the study group was significantly superior to that in the control group (P<0.05). After treatment, TXB2 level in the two groups was reduced, while 6-K-PGF1α was elevated, and those in the study group were significantly superior to those in the control group (P<0.05). After treatment, IMT in the two groups was reduced, and the reduced degree in the study group was significantly superior to that in the control group (P<0.05). Conclusions: Aspirin in combined with ozagrel sodium in the treatment of ACI can effectively inhibit the platelet aggregation, improve the coagulation function and cerebral blood supply, promote the recovery of cerebral nerve function after infarction, and enhance the therapeutic effect; therefore, it deserves to be widely recommended in the clinic.